MEF2C and acute lymphoblastic leukemia: MEF2C serves as an oncogene in an immature subtype of T-ALL and is aberrantly activated via NKL homeodomain TF NKX2-5 or by genomic upstream-deletions eliminating a repressive binding site for STAT5 [26–28].